Washington, Oct 11 (UNI) US President Donald Trump announced Friday that biopharmaceutical giant AstraZeneca will invest USD 50 billion in the United States over the next five years to support research and development of new medicines and expand domestic manufacturing.
“Furthermore, AstraZeneca will invest USD 50 billion in the United States over the next five years for research and development of new drugs and to onshore manufacturing facilities across the country—like the new plant that broke ground yesterday in Charlottesville, Virginia, where the governor attended,” Trump said during an event at the Oval Office.
The president noted that the Charlottesville facility is expected to initially create 3,600 jobs.
In addition to the investment, Trump revealed that AstraZeneca will offer significant discounts on its prescription drugs to American consumers. Under the “Most Favored Nation” pricing rule, Americans will pay no more than the lowest price available for those medications anywhere in the world.
Trump emphasized that the pricing reform would result in substantial savings for American taxpayers—potentially amounting to hundreds of millions of dollars annually.
